May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Oncothon: Pediatric Cancer Care Centralization In Netherlands and It’s Outcomes
Apr 23, 2024, 07:52

Oncothon: Pediatric Cancer Care Centralization In Netherlands and It’s Outcomes

Oncothon is a telethon spanning 24 hours, dedicated to gathering donations for childhood cancer research. Dr. Gertjan Kaspers who is a world-known pediatric oncology expert working at Princess Máxima Center for Pediatric Oncology in Utrecht, Netherlands. Dr. Kaspers will introduce their experience in pediatric cancer care centralization.

Speakers

Dr. Gertjan Kaspers is a pediatric oncologist specializing in acute myeloid leukemia and acute promyelocytic leukemia. Since 2013, he has served as the Director of the Academy and Outreach department at the Princess Máxima Center, which is a leading institution for pediatric cancer care in the Netherlands. Additionally, he holds the position of professor of pediatric oncology at Vrije University Amsterdam.

Prof. Kaspers research is primarily focused on leukemias, pediatric oncology in developing countries, as well as on brain tumors and quality of life. He has supervised 20 PhD students and successfully trained 31 PhD students. Furthermore, he is actively engaged in various outreach projects aimed at improving outcomes for children with cancer in low- and middle-income countries (LMICs). He chairs the I-BFM-SG Task Force on Outreach and is the founder of the Foundation World Child Cancer NL.

Beyond his roles in the Netherlands, Prof. Kaspers also holds visiting professorships at UZ Gent in Belgium, MTRH in Eldoret, Kenya, and UGM in Yogyakarta, Indonesia.

Moderator

Gevorg Tamamyan is the Editor-in-chief of OncoDaily, Head of the Pediatric Cancer and Blood Disorders Center of Armenia, Chairman and Professor of the Department of Hematology and Pediatric Oncology at Yerevan State Medical University, CEO of the Immune Oncology Research Institute, President-Elect of the Pediatric Oncology East and Mediterranean (POEM) Group. He is also the Adviser to the Rector of YSMU and to the Director of the Yeolyan Hematology and Oncology Center. He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.

Dr. Tamamyan is the Past-Chair of the American Society of Clinical Oncology (ASCO) IDEA Steering Group and International Society of Pediatric Oncology (SIOP) PODC Supportive care WG, Ambassador of the Society of Hematologic Oncology. He was selected for the ASCO Leadership Development Program and currently is a member of the ASCO International Committee. He is a recipient of numerous awards and distinctions, among them the ASCO IDEA and LIFe Awards, 40 under 40 in Cancer Award, he was recognized as a Young Leader of the International Agency for Cancer Research (IARC) and Union for International Cancer Control (UICC). 

For more detailed information about Dr. Tamamyan, you can visit the Immune Oncology Research Institute’s website.

00:15 – Introduction

00:45 – Netherland’s experience in pediatric cancer care centralization

2:54 – Armenia’s experience in pediatric cancer care centralization


About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.